ClinicalTrials.gg
RecruitingNCT074539923 TORIC ROTATEUpdated Mar 6, 2026

Postoperative Rotational Dynamics of Three Toric Intraocular Lens Designs

An interventional study of TECNIS Toric II (ZCU) and AcrySof IQ Toric in Cataract, sponsored by Jin Yang. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-06.

Sponsored by Jin Yang · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 1 year after the study started (first participant enrolled Jan 2025, registered Jan 2026).
  • Started Jan 2025; still recruiting 1 year 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
400
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 184 studies in Cataract with a site in China — 39 open to participants now, 49 under way, none of them phase 3. Cataract · China.

Planned enrollment
12th of 111
400 · median 90
Started
2025
with 14 others
No phase
104 of 184
19 open now
Primary completion
2026-10
later than 30 of 48 live
Registered
166th of 184
by date
Lead sponsor
6 of 184
Jin Yang

Among the 184 studies in Cataract with a site in China, this one is the 12th largest by planned enrollment of the 111 interventional ones that give a count, is one of 15 that started in 2025, is one of 104 with no phase, reaches primary completion later than 30 of the 48 other live ones, and was the 166th registered.

Cataract

1,633 studies on the registry are indexed under Cataract; 234 are open to participants now.

Browse Cataract studies →

Open to participants now

39 of the 184 studies in Cataract with a site in China are open now. Recruiting first, the newest first:

33 more — sign in →

All 39 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 143 Cataract studies recruiting now, 88 (62%) set no upper age limit and 8 (6%) stop at 75 or younger; 10 take children under 18; 15 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 184 studies in Cataract with a site in China, or all of them as a file.
02

Study summary

This prospective comparative cohort study evaluates and compares postoperative rotational stability and time-course dynamics of three commercially available toric intraocular lenses (TECNIS Toric II [ZCU], AcrySof IQ Toric, and AT TORBI 709M) after phacoemulsification cataract surgery. Rotation is quantified by registering postoperative retroillumination photographs to the end-of-surgery baseline using iris/scleral landmarks, with follow-up at postoperative day 1, day 3, week 1, week 2, month 1, and month 3. Associations between rotational outcomes and ocular biometric parameters are analyzed using linear mixed-effects models to inform individualized IOL selection and perioperative management.

03

Conditions studied

  • Cataract

Keywords

  • toric intraocular lens
  • rotational stability
  • cataract
  • astigmatism
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults aged 18 years or older with age-related cataract scheduled for phacoemulsification cataract surgery.
  • Presence of regular corneal astigmatism requiring toric intraocular lens implantation.
  • Eligible for implantation of one of the three study toric intraocular lenses based on preoperative evaluation.
  • Ability to understand the study procedures and provide written .

Exclusion criteria

Exclusion Criteria:

  • History of prior ocular surgery in the study eye.
  • History of ocular trauma in the study eye.
  • Irregular corneal astigmatism or corneal pathology affecting reliable biometric measurement.
  • Intraoperative complications, including anterior capsular tear or posterior capsular rupture.
  • Inadequate pupillary dilation during surgery or postoperative examinations.
  • Evidence of zonular weakness, zonular dialysis, or lens subluxation.
  • Active ocular infection or inflammation.
  • Any other ocular or systemic condition judged by the investigator to potentially affect intraocular lens stability or study outcomes.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
400 participants (estimated)

Study arms

  • Active comparator
    TECNIS Toric II (ZCU)

    Participants randomized to this arm receive implantation of the TECNIS Toric II (ZCU) intraocular lens during standard phacoemulsification cataract surgery.

    Device: TECNIS Toric II (ZCU)

  • Active comparator
    AcrySof IQ Toric

    Participants randomized to this arm receive implantation of the AcrySof IQ Toric intraocular lens during standard phacoemulsification cataract surgery.

    Device: AcrySof IQ Toric

  • Active comparator
    AT TORBI 709M

    Participants randomized to this arm receive implantation of the AT TORBI 709M intraocular lens during standard phacoemulsification cataract surgery.

    Device: AT TORBI 709M

Interventions

  • DeviceTECNIS Toric II (ZCU)

    Using TECNIS Toric II (ZCU) intraocular lens during standard phacoemulsification cataract surgery.

  • DeviceAcrySof IQ Toric

    Using AcrySof IQ Toric intraocular lens during standard phacoemulsification cataract surgery.

  • DeviceAT TORBI 709M

    Using the AT TORBI 709M intraocular lens during standard phacoemulsification cataract surgery.

06

What researchers measure

Primary outcomes

  1. Absolute rotational misalignment of toric intraocular lens (IOL) measured in degrees

    Absolute rotation of the implanted toric intraocular lens (IOL) relative to the intended axis, measured in degrees. Rotation will be quantified by registering postoperative retroillumination images to the end-of-surgery baseline frame using iris or scleral landmarks. The absolute rotation angle will be calculated for each follow-up visit.

    Time frame: Postoperative day 1, day 3, week 1, week 2, month 1, and month 3.

Secondary outcomes

  1. Uncorrected and corrected distance visual acuity (UDVA and CDVA)

    Uncorrected distance visual acuity (UDVA) and corrected distance visual acuity (CDVA) measured using a standardized logarithm of the minimum angle of resolution (logMAR) visual acuity chart during follow-up.

    Time frame: postoperatively on 1 day, 3 days, 1 week, 2 weeks, 1 month and 3 months

  2. Postoperative residual refractive astigmatism measured in diopters

    Residual refractive astigmatism measured by manifest refraction during follow-up visits and reported in diopters (D).

    Time frame: Postoperative day 1, day 3, week 1, week 2, month 1, and month 3.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2025 (actual). Primary completion is estimated for Oct 2026, 21 months after the start.

Of 304 non-industry interventional studies with no phase under Cataract, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 30. This study's planned 21 months is above that.

Counting every sponsor, half of 494 studies reached it within 17 months; a quarter within 9 and three quarters within 29.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 18, 2026
First posted
Mar 6, 2026
StartActual
Jan 1, 2025
Primary completionEst.
Oct 31, 2026
CompletionEst.
Dec 31, 2030
Last update
Mar 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07453992
Lead sponsor
Jin Yang
Responsible party
Jin Yang (Chief Physician, Eye & ENT Hospital of Fudan University) — Sponsor-investigator
First posted
Mar 6, 2026
Start date
Jan 1, 2025
Primary completion
Oct 31, 2026 (estimated)
Completion
Dec 31, 2030 (estimated)
Last update
Mar 6, 2026

Study contacts

Xuanqiao Lin
Contact
1532483480@qq.com
+8615088920668
Jin Yang
principal investigator · Fudan University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion